exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088003 RNA Name: hsa-miR-302a-3p RNA Type: miRNA Chromosome: chr4 Starnd: - Coordinate: Start Site(bp): 112648186 End Site(bp): 112648208 External Links: hsa-miR-302a-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ZBTB5 chr9 37438102 37465450 - PPP1R8 chr1 27830782 27851676 + ATP6V1C1 chr8 103021063 103073051 + SEC23B chr20 18507520 18561415 + FABP5 chr8 81280536 81284777 + THRAP3 chr1 36224432 36305357 + LONP2 chr16 48244300 48363122 + KLC1 chr14 103561896 103714249 + FAM222B chr17 28755978 28855232 - WASF3 chr13 26557683 26688948 + TOP2A chr17 40388525 40417896 - APP chr21 25880550 26171128 - ARL4A chr7 12686856 12690958 + PDRG1 chr20 31944337 31952046 - SCAMP2 chr15 74843730 74873365 - RAB31 chr18 9708275 9862551 + IKZF4 chr12 56007659 56038435 + RACGAP1 chr12 49976923 50033136 - MGLL chr3 127689062 128052190 - HABP4 chr9 96450169 96491336 + USP6NL chr10 11453946 11611754 - RGMA chr15 93035273 93089204 - JARID2 chr6 15246069 15522042 + BAZ1B chr7 73440406 73522293 - CLIP4 chr2 29097705 29189643 + IPO7 chr11 9384652 9448127 + SEC23IP chr10 119892730 119944657 + VLDLR chr9 2621787 2660056 + IZUMO2 chr19 50152548 50163195 - SSR1 chr6 7268306 7347446 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC011503.2 chr19 23927788 23929287 + AC125257.1 chr17 41848518 41851447 - AL049840.4 chr14 103694516 103695050 - ARHGAP27P1-BPTFP1-KPNA2P3 chr17 64749663 64781707 - FGD5-AS1 chr3 14920347 14948424 - MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.